TCRX
Income statement / Annual
Last year (2023), TScan Therapeutics, Inc.'s total revenue was $21.05 M,
an increase of 55.52% from the previous year.
In 2023, TScan Therapeutics, Inc.'s net income was -$89.22 M.
See TScan Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$21.05 M
|
$13.54 M
|
$10.14 M
|
$1.09 M
|
$0.00
|
| Cost of Revenue |
$88.15 M |
$5.14 M |
$3.33 M |
$20.58 M |
$519,000.00 |
| Gross Profit |
-$67.10 M |
$8.40 M |
$6.81 M |
-$19.49 M |
-$519,000.00 |
| Gross Profit Ratio |
-3.19 |
0.62 |
0.67 |
-17.96 |
0 |
| Research and Development
Expenses |
$88.15 M
|
$59.82 M
|
$44.95 M
|
$20.58 M
|
$9.44 M
|
| General & Administrative
Expenses |
$26.35 M
|
$20.35 M
|
$13.83 M
|
$6.74 M
|
$4.77 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$26.35 M
|
$20.35 M
|
$13.83 M
|
$6.74 M
|
$4.77 M
|
| Other Expenses |
$0.00 |
$1.59 M |
$16,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$114.51 M |
$80.17 M |
$58.78 M |
$27.32 M |
$14.21 M |
| Cost And Expenses |
$114.51 M |
$80.17 M |
$58.78 M |
$27.32 M |
$14.21 M |
| Interest Income |
$8.00 M |
$1.59 M |
$16,000.00 |
$106,000.00 |
$552,000.00 |
| Interest Expense |
$3.76 M |
$1.18 M |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$5.36 M
|
$5.14 M
|
$3.33 M
|
$1.23 M
|
$519,000.00
|
| EBITDA |
-$80.10 M
|
-$59.91 M
|
-$45.30 M
|
-$25.00 M
|
-$13.69 M
|
| EBITDA Ratio |
-3.81 |
-4.81 |
-4.47 |
-23.04 |
0 |
| Operating Income Ratio
|
-4.44
|
-4.92
|
-4.8
|
-24.18
|
0
|
| Total Other
Income/Expenses Net |
$4.24 M
|
$415,000.00
|
$16,000.00
|
$106,000.00
|
$552,000.00
|
| Income Before Tax |
-$89.22 M |
-$66.22 M |
-$48.63 M |
-$26.13 M |
-$13.66 M |
| Income Before Tax Ratio
|
-4.24
|
-4.89
|
-4.79
|
-24.08
|
0
|
| Income Tax Expense |
$0.00 |
-$415,000.00 |
$3.09 M |
-$106,000.00 |
-$552,000.00 |
| Net Income |
-$89.22 M |
-$65.81 M |
-$48.63 M |
-$26.02 M |
-$13.11 M |
| Net Income Ratio |
-4.24 |
-4.86 |
-4.79 |
-23.98 |
0 |
| EPS |
-1.36 |
-2.74 |
-2.03 |
-1.04 |
-0.53 |
| EPS Diluted |
-1.36 |
-2.74 |
-2.03 |
-1.04 |
-0.53 |
| Weighted Average Shares
Out |
$65.60 M
|
$24.05 M
|
$23.91 M
|
$24.94 M
|
$24.94 M
|
| Weighted Average Shares
Out Diluted |
$65.60 M
|
$24.05 M
|
$23.91 M
|
$24.94 M
|
$24.94 M
|
| Link |
|
|
|
|
|
